U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00734|||Q9UCA1
Gene ID: 2147.0
Gene Symbol: F2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ANGIOMAX

Approved Use

Angiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Launch Date

9.7683839E11
PubMed

PubMed

TitleDatePubMed
Development and current applications of thrombin-specific inhibitors.
2001 Jun
Bivalirudin: a new approach to anticoagulation.
2001 Mar-Apr
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
2002
Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
2002
New drugs 2002. Part II.
2002 Apr
Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy-- replacing heparin with bivalirudin.
2002 Apr
Building a stronger foundation: improved antithrombin therapy with bivalirudin in percutaneous coronary intervention.
2002 Apr
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
2002 Aug
Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty.
2002 Aug
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.
2002 Dec
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
2002 Fall
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
2002 Jun
Selective inhibition of coagulation factors: advances in antithrombotic therapy.
2002 Jun
The role of thrombin inhibition during percutaneous coronary intervention.
2002 Jun
Clinical pharmacology of bivalirudin.
2002 Jun
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
2002 Jun
Pharmacology and clinical use of bivalirudin.
2002 Jun
Reversing anticoagulants both old and new.
2002 Jun-Jul
Direct thrombin inhibitors.
2002 May 1
Gateways to clinical trials.
2002 Oct
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
2002 Oct 30
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
2002 Sep
Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
2003
Direct thrombin inhibitors in cardiac disease.
2003
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
2003 Apr
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
2003 Aug
Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass.
2003 Feb
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
2003 Feb 19
Should bivalirudin replace heparin during percutaneous coronary interventions?
2003 Feb 19
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
2003 Feb 19
Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass.
2003 Jan
Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits.
2003 Jul
Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected].
2003 Jul
Bivalirudin in peripheral vascular interventions: a single center experience.
2003 Jul
Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.
2003 Jul 15
Current anticoagulant therapy--unmet clinical needs.
2003 Jul 15
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study.
2003 Jun
Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions.
2003 Jun
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
2003 Mar
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study.
2003 Mar 15
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
2003 Mar 15
Predicting the pharmacology of thrombin inhibitors.
2003 May
Direct thrombin inhibitors.
2003 May
In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant.
2003 May
An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study.
2003 May
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
2003 May 1
A 24-hour continuous infusion study of bivalirudin in the rat.
2003 May-Jun
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials.
2003 Oct 15
Bivalirudin in percutaneous coronary intervention.
2003 Sep 15
Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin.
2004 Jan 15
Patents

Sample Use Guides

The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration: Intravenous
Substance Class Protein
Created
by admin
on Sat Dec 16 16:59:54 UTC 2023
Edited
by admin
on Sat Dec 16 16:59:54 UTC 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
TN9BEX005G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIVALIRUDIN
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
bivalirudin [INN]
Common Name English
BIVALIRUDIN [ORANGE BOOK]
Common Name English
BIVALIRUDIN [VANDF]
Common Name English
BIVALIRUDIN [MART.]
Common Name English
Bivalirudin [WHO-DD]
Common Name English
BIVALIRUDIN [EMA EPAR]
Common Name English
BG-8967
Code English
L-LEUCINE, D-PHENYLALANYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYLGLYCYLGLYCYLGLYCYL-L-ASPARAGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-PROLYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-
Systematic Name English
BIVALIRUDIN [MI]
Common Name English
BIVALIRUDIN [USP-RS]
Common Name English
BG8967
Code English
BIVALIRUDIN [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AE06
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
FDA ORPHAN DRUG 200204
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
NDF-RT N0000175980
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
NDF-RT N0000175518
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
NCI_THESAURUS C263
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
Code System Code Type Description
SMS_ID
100000085243
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
DAILYMED
TN9BEX005G
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
RS_ITEM_NUM
1076013
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
EVMPD
SUB05862MIG
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
DRUG CENTRAL
385
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
MERCK INDEX
m2581
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
DRUG BANK
DB00006
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
CAS
128270-60-0
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
USAN
FF-67
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
CHEBI
59173
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
NCI_THESAURUS
C47415
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
FDA UNII
TN9BEX005G
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
WIKIPEDIA
Bivalirudin
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID00155847
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
INN
7282
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
LACTMED
Bivalirudin
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
RXCUI
60819
Created by admin on Sat Dec 16 16:59:55 UTC 2023 , Edited by admin on Sat Dec 16 16:59:55 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC